ARS Pharmaceuticals's total assets for Q1 2025 were $327.32M, a decrease of -6.79% from the previous quarter. SPRY total liabilities were $98.34M for the fiscal quarter, a 4.23% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.